Head of Brand, Communications and Engagement, Brandon Capital
| Role | Organisation | Sources |
|---|---|---|
| Head of Brand, Communications and Engagement (former) | Brandon BioCatalyst | Brandon BioCatalyst, Brandon Capital |
| Head of Brand, Communications and Engagement | Brandon Capital | Brandon Capital (19 Dec 2024), Brandon Capital (13 May 2024), Brandon BioCatalyst |
Stories naming Kirrily Davis. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.
CUREator, Brandon BioCatalyst's government-backed grant program, has awarded $7.21 million across eight Australian biotech firms in its newest round, split between clinical-stage and preclinical recipients.
Also Brandon BioCatalyst portfolio·Startup Daily·ausceleratesa.org